• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Improved survival with bufulfan-cyclophosphamide combination vs total body irradiation

byAndrew Bishara
September 28, 2013
in Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. IV busulfan combined with cyclophosphamide (BuCy) is associated with better leukemia-free and overall survival in acute myeloid leukemia (AML) than total body irradiation (TBI).

2. Improved outcomes and greater ease of administration favor BuCy over Cy/TBI for AML patients in first complete remission (CR) undergoing hematopoietic cell transplantation (HCT).

Evidence Rating Level: 2 (Good)

Study Rundown: The most common myeloablative conditioning regimens for allotransplant in AML patients include cyclophosphamide combined with TBI (Cy/TBI) or busulfan (BuCy). However, there are few comparisons of the outcomes of patients receiving these treatments, particularly in light of recent improvements in busulfan administration. Therefore, the goal of this study was to examine the long-term outcomes between these different treatment approaches. The authors found that IV Bu had significantly better outcomes in terms of leukemia free and overall survival. Given the reduced technical requirements of Bu administration compared to TBI, this supports further investigation into the uses of Bu in lieu of the traditional Cy/TBI therapy for this particular patient population. These results benefit from the large number of patients enrolled and the involvement of multiple institutions. However, it should be noted that this was a retrospective study, and patients were not randomly assigned to specific conditioning regimes. Though multivariate analysis corrected for demographic differences between the two treatment groups, several patient characteristics did vary such as age and year of transplantation. There was also variation in the dose of TBI, Bu and Cy. Therefore, future prospective studies into these treatment options may be necessary.

Click to read the study in Blood

RELATED REPORTS

Venetoclax plus azacitidine demonstrating efficacy for high-risk myelodysplastic syndromes

Brentuximab-based chemotherapy improves survival and reduces toxicity in patients with advanced Hodgkin lymphoma

#Visual Abstract: Targeted Agents Combined with CHOP Increased Response Rates for Peripheral T-Cell Lymphoma

Relevant Reading: One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation

In-Depth [retrospective cohort study]: The authors of this study conducted a large, retrospective review of patients from over 500 transplant centers who had undergone first allogeneic HCT with HLA-identical siblings or unrelated donors between 2000 and 2006 for AML in first remission. They examined a total of 1230 patients who had undergone Cy/TBI or BuCy without additional agents, with a median follow-up of surviving patients of 5 years. The primary outcome measured was survival. Other information collected included relapse as defined by hematologic criteria, time to neutrophil and platelet recovery and graft-versus-host disease. The estimated leukemia-free survival and overall survival at 5 years was 41% (95% CI: 37-46%) and 43% (95% CI: 39-47%) for the TBI group, 54% (95% CI: 49-60%)and 61% (95% CI: 56-66%) for oral Bu and 57% (95%CI: 50-64%) and 58% (95% CI: 51-65%) for IV Bu (P < 0.001 for each).

By Monica Parks and Andrew Bishara

More from this author: Adjuvant radiotherapy reduces recurrence of ductal carcinoma; no effect on long-term prognosis, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

 © 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: acute myeloid leukemiaAMLbusulfancyclophosphamideleukemiatotal body irradiation
Previous Post

Secondary mastoid obliteration improves quality of life for patients with chronic otitis media

Next Post

The CRASH-2 trial: Tranexamic acid in trauma patients [Classics Series]

RelatedReports

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden
Oncology

Venetoclax plus azacitidine demonstrating efficacy for high-risk myelodysplastic syndromes

March 20, 2025
Niraparib may lengthen progression-free survival for patients with recurrent ovarian cancer
Chronic Disease

Brentuximab-based chemotherapy improves survival and reduces toxicity in patients with advanced Hodgkin lymphoma

August 28, 2024
#Visual Abstract: Targeted Agents Combined with CHOP Increased Response Rates for Peripheral T-Cell Lymphoma
StudyGraphics

#Visual Abstract: Targeted Agents Combined with CHOP Increased Response Rates for Peripheral T-Cell Lymphoma

August 8, 2024
#VisualAbstract: Blinatumomab Improves Survival in MRD-Negative Acute Lymphoblastic Leukemia in Adults
StudyGraphics

#VisualAbstract: Blinatumomab Improves Survival in MRD-Negative Acute Lymphoblastic Leukemia in Adults

August 5, 2024
Next Post

The CRASH-2 trial: Tranexamic acid in trauma patients [Classics Series]

Pediatric post-operative intussusception more common in open surgery

Enriching fat grafts with stem cells improves outcomes

Less than one-fifth of patients with hypertension worldwide well controlled

Hypertensive disorders of pregnancy associated with future renal disease

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Living in a marginalized neighbourhood is associated with worse outcomes in patients with myocardial infarction
  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.